TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
Accesswire
*TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeks*
*Eighty percent (80%)..